Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03208244 · ClinicalTrials.gov registry record · Phase 4
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT03208244: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03208244 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03208244, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a proof of concept, single center study for the donation of HCV-positive hearts to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.
Interventions
- DRUG Clinically prescribed direct acting antiviral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-11-09 |
| Est. Completion | 2021-04-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03208244
The ClinicalTrials.gov registry entry for NCT03208244 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clinically prescribed direct acting antiviral is the first listed.
NCT03208244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03208244 about?
NCT03208244 is a clinical study titled "DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant". This is a proof of concept, single center study for the donation of HCV-positive hearts to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.
What is the current status of trial NCT03208244?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2017-11-09. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT03208244?
The interventions under investigation include: Clinically prescribed direct acting antiviral (DRUG).
Who is sponsoring clinical trial NCT03208244?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.